Genentech to Present Important New Data Reflecting Broad Cancer Pipeline at ... The Herald | HeraldOnline.com The Phase III study CLL11, which is being conducted in close collaboration with the German CLL Study Group (GCLLSG), compared the combination of either GA101 or Rituxan® (rituximab) and standard chemotherapy (chlorambucil) to chlorambucil alone. |
